GDP-fucose—the precise “donor” and “key” of the world of glycosylation

Guanosine diphosphate-5′-fucose (GDP-fucose) is an indispensable key active sugar nucleotide donor in fucosylation reactions in vivo. It is not only a core molecule in basic glycobiological research, but also a strategic raw material used to precisely regulate biological activity in drug development (especially antibody drugs, vaccines and cell therapy).

Chemical Information

· Chemical name: 5′-guanosine diphosphate-β-L-fucose disodium salt

· Common name: GDP-fucose

· English name: Guanosine5′-diphospho-β-L-fucose, sodium salt

· Chemical formula: C16H23N5O15P2 · xNa (commonly disodium salt)

· Molecular weight: 589.34g/mol (free acid)

· CAS number: 15839-70-0

Structural features

The structure of GDP-fucose brings together the essence of its function:

· High-energy sugar nucleotide structure: A guanine nucleoside is connected to a diphosphate group through its 5'-position, and the diphosphate group is then connected to β-L-fucose. This structure is the chemical basis for its role as an "activated sugar" donor.

· Unique L-configuration fucose: Unlike the common D-configuration sugar, fucose is a rare L-configuration six-carbon sugar, which makes the sugar structure it participates in the construction of have unique spatial conformation and biological specificity.

· "Donor" core: Under the catalysis of fucosyltransferase, GDP-fucose can accurately transfer fucose groups to specific acceptor sites on sugar chains, proteins or lipids, thus determining the "language" of intercellular communication.

Main applications and advantages

1. Core tools for glycoprotein drug optimization

· Enhance antibody effector function: The core fucosylation level of the Fc segment of an antibody is a key factor in determining its ADCC (antibody-dependent cell-mediated cytotoxicity) effect. Using an in vitro enzymatic catalytic system and regulating the supply of GDP-fucose, defucosylated or hypofucosylated antibodies can be produced. The affinity of such antibodies to immune cells is significantly enhanced, and the drug efficacy can be increased ten to one hundred times. This is the core technology of a new generation of anti-cancer antibody drugs such as obinumab.

· Improve the pharmacokinetics of therapeutic proteins: Precise fucose modification of therapeutic proteins (such as EPO, coagulation factors) can affect their half-life and stability in the body, thereby optimizing efficacy.

2. Enabler of cell therapy and vaccine development

· Regulating immune cell homing: Fucosylation modifications on the cell surface (such as selectin ligands) are key to mediating the "homing" of immune cells to inflammatory sites or lymphoid organs. In the development of cell therapy products such as CAR-T and TCR-T, the targeted migration ability and infiltration efficiency of therapeutic immune cells can be enhanced by regulating GDP-fucose metabolism.

· Vaccine antigen design: The fucosylation pattern on the surface of pathogens (such as viruses and bacteria) is an important feature of their immune recognition. Utilizing GDP-fucose can be used to synthesize or reconstitute key fucosylated antigens for the development of multivalent vaccines.

3. Basic research and biomarker discovery

· Glycobiology “decoding” tool: As an exclusive substrate for fucosyltransferase, GDP-fucose is an essential reagent for studying the function of fucosylation in development, immunity, cancer, and genetic diseases.

· Disease diagnostic potential: Abnormal fucosylation patterns are important biomarkers in a variety of diseases (such as cancer, congenital glycosylation disorders). GDP-fucose is a reliable raw material for constructing detection standards and developing diagnostic methods.

Conclusion

Guanosine diphosphate-5′-fucose (GDP-fucose) is much more than a biochemical molecule, it is a critical bridge between the genetic blueprint and the complex functions of life. From designing "smart bomb"-style precision antibodies, to arming cells with "living drugs", to decoding the sugar code of diseases, their value is being rapidly discovered.